Europe Next-Generation Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Targeted Therapy (Small Molecule Inhibitors), Immunotherapy Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4) CAR-T Cell Therapy Cancer Vaccines, Gene Therapy, Cell Therapy (e.g., TILs, NK cells) ), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancers (Leukemia, Lymphoma, Myeloma) ), By Country (U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux) and Forecast, 2026-2034

Europe Next-Generation Cancer Therapeutics Market Trends

Biomarker-Directed and Combination Oncology Accelerates

Precision oncology is shifting treatment selection toward genomic profiling, mutation-specific inhibitors, ADCs and immune combinations. Approximately 2.7 million EU cancer diagnoses and 1.3 million deaths provide a substantial treatment pool, while 25 new cancer medicines received positive opinions in 2023, equivalent to around one-third of medicines reviewed positively by EMA that year.

Regulatory throughput remains high: EMA recommended 28 oncology products in 2024, while 104 medicines overall were recommended in 2025, including 38 new active substances. Diagnostic-guided treatment is increasingly embedded in development, with about 33% of EU oncology/haematology authorisations during 2010–2024 involving diagnostic patient selection.

Europe Next-Generation Cancer Therapeutics Market Drivers

Rising Cancer Burden and Precision-Oncology Adoption

Europe accounts for approximately 25% of global cancer diagnoses, with 2.7 million new EU cases and 1.3 million deaths recorded in 2022. Without additional action, cancer-related deaths are projected to rise 24% by 2035. These volumes are increasing demand for molecular testing, checkpoint inhibition, mutation-directed drugs and engineered cellular treatments; approximately one-third of EU oncology/haematology authorisations from 2010–2024 already depended on diagnostic identification of eligible patients.

Europe Next-Generation Cancer Therapeutics Market Restraints

Complex Manufacturing, Evidence Requirements and Treatment Access

Advanced therapeutics face manufacturing, reimbursement and evidence-generation constraints across multiple national systems. EMA recommended 104 medicines in 2025 but issued 7 negative opinions, while 20 applications were withdrawn before CHMP opinion, frequently because submitted evidence was insufficient. With cancer responsible for approximately 1.3 million EU deaths in 2022 and projected mortality potentially increasing 24% by 2035, unequal diagnostic and treatment access remains commercially significant.

Europe Next-Generation Cancer Therapeutics Market Opportunities

Combination Regimens and Molecular Patient Selection Expand Addressable Populations

Combination therapy creates opportunities to integrate checkpoint inhibitors, targeted agents, ADCs and endocrine or molecular treatments. In May 2026, CHMP supported Keytruda plus enfortumab vedotin for eligible muscle-invasive bladder cancer and recommended 3 additional adolescent indication extensions for Keytruda injection. During the same month, CHMP recommended 8 new medicines and 13 indication extensions, indicating continued regulatory expansion of treatment populations.

Challenges in Europe Next-Generation Cancer Therapeutics Market

Patient Stratification and Sustainable Treatment Optimisation

The industry must balance rapid innovation with evidence quality, toxicity management and biomarker availability. EMA's June 2026 Cancer Medicines Forum prioritized treatment optimisation, toxicity-benefit assessment, pragmatic trials and diagnostic-guided treatment strategies. Meanwhile, global evidence indicates 37%, or approximately 7.1 million, of 2022 cancer cases were associated with preventable causes, adding prevention-driven uncertainty to long-range treatment demand.

Europe Next-Generation Cancer Therapeutics Market Segmentation

Therapy segmentation shows targeted therapy holding approximately 36.1% of the 2026 therapy-table total, followed by immunotherapy at 22.0%, gene therapy at 15.7%, cell therapy at 10.1%, ADCs at 9.7%, and RNA-based therapeutics at 6.5%.

By Therapy Type

Targeted Therapy (Small Molecule Inhibitors) leads with USD 7,870.11 million in 2026, reaching USD 15,015.35 million by 2034 at 8.41% CAGR. Immunotherapy follows at USD 4,786.75 million in 2026 and USD 9,065.45 million by 2034.

Targeted therapy is also the fastest-growing listed therapy at 8.41% CAGR, narrowly ahead of immunotherapy at 8.31%. Gene therapy records 7.86%, ADCs 7.73%, cell therapy 7.66%, and RNA-based therapy 7.61%.

By Cancer Type

Lung, breast, colorectal, blood, prostate, brain, and pan-tumor cancers constitute the principal cancer-type segmentation. The supplied tables do not assign market values or CAGRs to these subsegments; therefore, no unsupported numerical allocation is introduced. The overall country dataset advances from USD 21,781.94 million in 2026 to USD 40,282.81 million in 2034, at 7.6% CAGR.

Lung and breast cancers remain major precision-treatment targets, supported by targeted inhibitors, ADCs, and checkpoint combinations. Europe’s approximately 2.7 million annual cancer diagnoses reinforce broad therapeutic demand, while the supplied therapy dataset shows targeted and immune therapies jointly representing about 58.0% of 2026 value.

By Modality

Monotherapy and combination therapy represent the core modalities, with combinations spanning immunotherapy plus targeted drugs, chemotherapy plus ADCs, and mRNA plus checkpoint inhibitors. The supplied dataset provides no modality-specific values; consequently, the USD 21,781.94 million 2026 country total and 7.6% overall CAGR serve only as market-level reference points.

Combination development is increasingly relevant as targeted therapy and immunotherapy together account for approximately 58.0% of the supplied 2026 therapy total. No separate fastest-growing modality CAGR is provided in the mandatory dataset.

By Route of Administration

IV, oral, intratumoral/localized, and subcutaneous delivery support different therapeutic architectures. Oral delivery benefits small-molecule inhibitors, while IV administration remains important across antibodies, ADCs, and cellular regimens. Targeted therapy alone contributes USD 7,870.11 million in 2026 and 36.1% of therapy value.

No route-specific CAGR is supplied. At the therapy level, the highest available CAGR is 8.41% for targeted therapy, compared with 7.73% for ADCs and 7.66% for cell therapy.

By Mechanism of Action

Immune activation, oncogene targeting, DNA-damage response modulation, tumor-microenvironment modulation, and apoptosis induction form the mechanism segmentation. Oncogene-targeting therapies are represented strongly by the USD 7,870.11 million targeted-therapy category in 2026, rising to USD 15,015.35 million by 2034.

The closest supplied mechanism proxy, targeted therapy, records the highest listed CAGR of 8.41%, while immunotherapy—closely associated with immune activation—records 8.31%. No standalone mechanism-level CAGR is supplied.

By End-User

Specialized cancer hospitals, academic/research institutes, ambulatory infusion centers, and homecare settings constitute major end users. Institutional channels remain important for cell therapies, ADCs, and IV immunotherapies, together representing more than 40% of the supplied 2026 therapy value when the immunotherapy, cell therapy, and ADC categories are combined.

The mandatory dataset contains no end-user-specific CAGR. The overall country dataset records 7.6% CAGR, while individual therapy growth ranges from 7.61% to 8.41% through 2034.

Europe Next-Generation Cancer Therapeutics Market Counties Outlook

U.K.

The U.K. represents approximately 22.9% of the supplied 2026 European country total, at USD 4,987.07 million, rising to USD 9,142.20 million by 2034 at 7.87% CAGR. Its contribution is second only to Germany.

Germany

Germany leads with USD 5,447.72 million in 2026, approximately 25.0% of the country total, and reaches USD 10,105.77 million by 2034 at 8.03% CAGR. The country therefore contributes roughly one-quarter of supplied European value.

France

France accounts for approximately 15.1% in 2026, valued at USD 3,280.13 million. It reaches USD 6,258.15 million by 2034, posting the fastest country CAGR at 8.41%.

Spain

Spain contributes approximately 8.0%, with USD 1,745.21 million in 2026, increasing to USD 3,266.32 million by 2034. Its 8.15% CAGR places it above the overall country-table rate.

Italy

Italy contributes approximately 10.0%, valued at USD 2,173.59 million in 2026 and USD 3,920.04 million by 2034. The country records 7.65% CAGR.

Russia

Russia represents approximately 8.1% of 2026 value, at USD 1,755.56 million, reaching USD 3,310.07 million by 2034. Its 8.25% CAGR is the second-highest listed country rate.

Nordic

Nordic countries account for approximately 5.2%, with USD 1,142.96 million in 2026 and USD 2,041.48 million in 2034, corresponding to 7.52% CAGR.

Benelux

Benelux contributes approximately 5.7%, valued at USD 1,249.70 million in 2026 and USD 2,238.78 million by 2034. The region registers 7.56% CAGR.

Top players in Europe's next-generation cancer therapeutics market

1. Roche
2. AstraZeneca
3. Merck & Co.
4. Bristol Myers Squibb
5. Novartis
6. Pfizer
7. Johnson & Johnson
8. Amgen
9. Gilead Sciences
10. Sanofi
11. Daiichi Sankyo
12. Takeda Pharmaceutical
13. Bayer
14. Ipsen
15. BeiGene

Top Two Companies

• Roche:Roche maintains a broad European oncology position across targeted medicines, antibodies, immuno-oncology and biomarker-linked treatment pathways. Approximately33%of EU oncology/haematology authorisations from 2010–2024 relied on diagnostic patient identification, reinforcing the strategic relevance of integrated diagnostics and precision therapeutics. A reliable company-specific percentage of the supplied market cannot be calculated from the mandatory tables, so no fabricated company share is assigned.
• AstraZeneca:AstraZeneca holds strong positioning across lung, breast and biomarker-driven oncology, including targeted and combination approaches. In May 2026, CHMP issued a positive opinion for AstraZeneca's camizestrant-based Etcamah in ESR1-mutated ER-positive/HER2-negative advanced or metastatic breast cancer, including use with3 specified CDK4/6 inhibitors. The supplied dataset does not disclose company-level percentages, preventing defensible calculation of an individual company share.

Recent Developments in the Europe Next-Generation Cancer Therapeutics Market

• 2026: Imdylltra (tarLatin Americaab) received EU marketing authorization on 29 May 2026 for extensive-stage small-cell lung cancer after progression on or following first-line platinum chemotherapy.
• 2026: Ojemda (tovorafenib) received conditional EU authorization on 20 April 2026 for eligible pediatric low-grade glioma with BRAF alterations after prior systemic treatment.
• 2026: Aumseqa (aumolertinib) received EU marketing authorization on 12 February 2026 for specified EGFR-mutated advanced NSCLC populations.

Research Methodology

The analysis uses the supplied 2025, 2026 and 2034 mandatory country and therapy tables as the primary quantitative source. Country percentages were calculated against the supplied USD 21,781.94 million 2026 country total, while therapy percentages were calculated against the separately supplied USD 21,806.45 million therapy total. The difference between the two source totals was retained rather than normalized. External evidence was limited to authoritative EMA, WHO and IARC information for cancer burden, regulatory activity and recent developments; no unsupported country, segment or company values were substituted for the mandatory dataset.